PPARα-independent action against metabolic syndrome development by fibrates is mediated by inhibition of STAT3 signalling.

ABSTRACT:

Objectives

Metabolic syndrome (MS) is the concurrence of at least three of five medical conditions: obesity, high blood pressure, insulin resistance, high serum triglyceride (TG) and low serum high-density lipoprotein levels. While fibrates are used to treat disorders other than the lowering serum TG, the mechanism by which fibrates decrease MS has not been established.

Methods

In this study, wild-type and Ppara-null mice fed a medium-fat diet (MFD) were administered gemfibrozil and fenofibrate for 3 months respectively, to explore the effect and action mechanism.

Key findings

In Ppara-null mice, MFD treatment increased body weight, adipose tissue, serum TG and impaired glucose tolerance. These phenotypes were attenuated in two groups treated with gemfibrozil and feno

SUBMITTER: Hua H 

PROVIDER: S-EPMC6281295 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature